Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals, Inc. Announces Successful Completion of $17 Million Private Offering
Arena Pharmaceuticals, Inc. Announces Successful Completion of $17 Million Private Offering SAN DIEGO, Feb. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena ™ ), a privately-held biotechnology company, has announced the successful completion of a private offering through the sale of its
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Successful Completion of Phase I Clinical Study of Novel
Potential New Treatment for Alzheimer's Disease
View HTML
Toggle Summary Neurocrine Biosciences and Arena Pharmaceuticals Announce Receptor Collaboration
Neurocrine Biosciences and Arena Pharmaceuticals Announce Receptor Collaboration SAN DIEGO, Sept. 15 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced a collaboration involving the
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Awarded Phase I SBIR Grant To Develop Novel, Atypical Antipsychotics
Target Is Constitutively Activated Form of Human Serotonin Receptor
View HTML
Toggle Summary Arena Pharmaceuticals Begins Receptor Drug Discovery Collaboration With Fujisawa
Arena Pharmaceuticals Begins Receptor Drug Discovery Collaboration With Fujisawa SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have
View HTML
Toggle Summary Lilly and Arena Form Drug Discovery Alliance
Lilly and Arena Form Drug Discovery Alliance INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening
View HTML
Toggle Summary Arena Pharmaceutucals to offer 5 million shares in IPO
Arena Pharmaceutucals to offer 5 million shares in IPO WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share
View HTML
Toggle Summary Arena Pharmaceutcals raises IPO to 6 mln shares
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
View HTML
Toggle Summary Arena prices 6 mln IPO at $18/shr, above range
Arena prices 6 mln IPO at $18/shr, above range NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq: ARNA - news ) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the lead underwriters.
View HTML
Toggle Summary New issues ride investor dreams amid Nasdaq selloff
By Denise Duclaux
View HTML